clinical trial · NCT07286266
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline·phase3·not yet recruiting·n = 450
Ovarian NeoplasmsGSK5733584PaclitaxelPegylated liposomal doxorubicin (PLD)TopotecanGemcitabine
brief summary
This study specifically aims to evaluate how well GSK5733584 works in treating ovarian cancer compared to standard treatments. The study also assesses whether GSK5733584 is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
started
Jun 24, 2026
primary completion
Jul 22, 2030
completion
Jul 22, 2030
last updated
Mar 19, 2026
official title
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol